fbpx

Brain Cancer

Diffuse Astrocytoma

Female, 50 years

Patient Internal 9522929

ICD-10 code

C71.1 Malignant Neoplasm of Frontal Lobe

Diagnosis (Incl. Metastases/Stage) and Year

August 2022
Diffuse Astrocytoma, G4 according to WHO, IDH(+) ATRX(+), TP53(+), no MGMT Methylation, Ki67 – 30%.

Previous Treatment

Surgery, Radiation Therapy, Chemotherapy (Temozolomide), Target Therapy (Bevacizumab).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis.

Treatment Provided

Autologous DCV (5 doses) and CIK (4 doses) over a period of 3 months. Additionally, the patient received nasal drops of Exosomes with Paclitaxel.

Patient Survival/Condition and Year
Date of Review: 15/10/2023

The patient has survived for 14 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Surgery, Radiation Therapy, Chemotherapy and Target Therapy, has exceeded the median survival. She is under the care of her husband. Her condition is stable, but requires assistance for daily needs.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.